VYNE — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-05-15

• We are developing VYN202, an oral, small molecule BD2-selective BET inhibitor. VYN202 has been designed to achieve potential class-leading potency and selectivity for BD2 vs. BD1. By maximizing BD2 selectivity, we believe VYN202 has the potential to be a potent oral immunomodulator option for both a…

• Until July 2025, our lead product was repibresib gel (also known as VYN201), a topically administered, small molecule pan-bromodomain (“BD”) BET inhibitor designed as a “soft” drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic expos…

• In August 2025, our board of directors initiated a strategic review to evaluate a range of options to maximize stockholder value, including the assessment of our internal pipeline, financing opportunities and strategic alternatives. Following the strategic review, we entered into an Agreement and Pl…

• Following the strategic review described above, on December 17, 2025, we entered into the Merger Agreement with Yarrow, a privately held biotechnology company advancing YB-101 (also known as GS-098), a clinical-stage, humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor f…

• In connection with the execution of the Merger Agreement, certain institutional and accredited investors (the "Series A Investors", led by an affiliate of RTW Investments) and Yarrow entered into a Series A stock purchase agreement, pursuant to which such persons invested in and purchased an aggrega…

Text removed vs the prior filing · source: 10-Q · 2025-11-06

• We are developing VYN202, an oral, small molecule BD2-selective BET inhibitor. VYN202 has been designed to achieve potential class-leading potency and selectivity for BD2 vs. BD1. By maximizing BD2 selectivity, we believe VYN202 has the potential to be a potent oral immunomodulator option for both a…

• In April 2025, the U.S. Food and Drug Administration ("FDA") verbally placed a clinical hold on our Phase 1b trial evaluating VYN202 in subjects with moderate-to-severe plaque psoriasis following an observation of testicular toxicity in dogs from a non-clinical toxicology study of VYN202. In June 20…

• Following the clinical hold, we unblinded the clinical data from the seven subjects who were enrolled in the trial (VYN202 treated: n=6 across 0.25 mg, 0.5 mg and 1 mg doses; placebo treated: n=1). All subjects treated with VYN202 had an improvement in signs and symptoms of disease, while the subjec…

• Based on this data, together with promising results from multiple preclinical models, we terminated the Phase 1b psoriasis trial in support of continued advancement of VYN202 into other serious, immune-mediated diseases with more limited effective treatment options.

• We have also evaluated VYN202 in preclinical studies in areas such as nephrology, pulmonology, rheumatology and myeloproliferative neoplasms, among others. The preclinical and translational data obtained support the potential of VYN202 as a potent, disease-modifying therapy for the treatment of seri…

Text added vs the prior filing · source: 10-Q · 2026-05-15

• On May 14, 2026, Yarrow Bioscience, Inc. entered into an employment agreement (the “Employment Agreement”) with our Chief Financial Officer, Tyler Zeronda, in connection with the Merger. Pursuant to the Employment Agreement, Mr. Zeronda was offered a position as Chief Financial Officer of the Combin…

• In the event of a termination of his employment without Cause or if he resigns for Good Reason (each, as defined in the Employment Agreement), subject to Mr. Zeronda’s execution of a release of claims, Mr. Zeronda will receive (i) a severance payment equal to nine months of his base salary then in e…

• In addition, if Mr. Zeronda’s employment is terminated by the Combined Company without Cause or if he terminates his employment with Good Reason within the 12 month period after a Change of Control (as defined in the Combined Company’s 2026 Stock Incentive Plan), he will be entitled to receive a cha…

• The foregoing description is not complete and is qualified in its entirety by reference to the full text of the Employment Agreement, a copy of which is filed as Exhibit 10.1 to this Quarterly Report on Form 10-Q and is incorporated herein by reference.

• In recognition of Mr. Zeronda’s contributions to VYNE and the benefit of Mr. Zeronda continuing as the Combined Company’s Chief Financial Officer following the Merger, on May 14, 2026, VYNE’s Compensation Committee approved a one-time transaction bonus for Mr. Zeronda equal to his target annual cash…